Andere talen OPKO Health, Inc.

Aandelen

OPK

US68375N1037

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,3 ^USD	0,00%		+6,56%	-13,91%

28/03	Laboratory Corp of America neemt bepaalde activa van BioReference's Diagnostics Business over	MT
20/03	Entera Bio kondigt robuuste farmacokinetische gegevens aan voor de eerste orale behandeling met glp-2 peptidetabletten voor patiënten met het korte darmsyndroom	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024	03/05
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations	01/04
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	28/03
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
OPKO Health : Immediate Report	15/03
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	14/03
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	13/03
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	12/03
OPKO Health - AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	06/03
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	05/03
OPKO Health : Immediate Report	02/03
OPKO Health : Report of Periodic or Interim Report	02/03
OPKO Health: Q4 Earnings Snapshot	27/02
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	27/02
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results	27/02
Drugmakers deepen efforts to tap into booming market for obesity drugs	27/02
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?	23/02
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen OPKO Health, Inc.

Aandelen

OPK

US68375N1037

Andere talen

Filters